Professor John Fitzpatrick from the Mater Hospital, Dublin has recently reviewed the status of drugs in development for the treatment of prostate cancer. His ®ndings suggest that there are currently about 139 drugs at varying stages of development. The majority of these are at the preclinical stage (72), with approximately equal numbers at phase I (24) and phase II (31). As one might expect, just ®ve are at phase III and three at pre-registration. These drugs have a diverse range of activities (Table 1) . Agents with hormonal activity include luteinizing hormone-releasing (LHRH) agonists and antagonists, 17,20 lyase inhibitors, 5a±reductase inhibitors, androgen receptor antagonists and cytochrome P450 oxidoreductase inhibitors. Examples of hormonal drugs as well as the companies involved are detailed in Table 2 . A diverse range of cell cycle inhibitors are in development, targeted at different stages of the cell cycle (Table 3) . There are also a number of apoptosis agonists at the preclinical stage, as well as angiogenesis inhibitors at preclinical and phases I and II (Table 4) .
Correspondence: Dr C McKillop, 4 Walkers Road, Longwick, Princes Risborough, Bucks, HP27 9SS Although comparable results between treatments were noted in the low-risk group, the risk of recurrence in patients in the high-risk group given brachytherapy, with or without prior hormone treatment, was three-fold higher than in those given either of the other treatments. In patients in the intermediate-risk group given brachytherapy alone, the risk was also increased three-fold; however, patients given hormone therapy prior to brachytherapy, had similar disease recurrence to those in the other treatment groups. Brachytherapy is a popular treatment option in the USA in men with cancers of all types. It is less risky than surgery, with a lower likelihood of causing incontinence and erectile dysfunction. These new data indicate that brachytherapy should be restricted to patients with low-risk prostate cancer. Interestingly, this will probably increase its usage in the future, as this type of prostate cancer represents 23± 45% of cancers detected by PSA screening.
A new prognostic indicator for prostate cancer
A recent study suggests that the level of p27 may help identify patients with more aggressive prostate cancers, which have a higher rate of recurrence and are associated with poorer long-term survival (Cordon-Cardo et al J Natl Cancer Inst 1998; 90: 1284±1291). Results indicate that p27 was abundant in tissue from a normal prostate gland, but was present in variable amounts in tumorous tissue. Aggressive cancers appear to degrade p27, reducing the level of this tumour suppressor protein. In more slow growing malignancies, measurable levels of the protein were still expressed. The authors of the new study proposed that p27 acted like a brake that kept cell growth in check. Reduced levels of p27 consequently allowed cells to proliferate more rapidly.
p27 has been shown to play an important role in controlling the growth of at least four different cancers originating from epithelial tissue: breast, colon, lung and oesophagus. Degradation of p27 by colon cancers has previously been described by Massimo Loda and Miguele Pagano. The implications for this trend are that by measuring p27 levels in tumour tissue, doctors may be able to identify more aggressive cancers and provide a more appropriate treatment regimen. It may also be possible to use p27 level to grade tumours when they are small and dif®cult to grade by existing methods, therefore allowing treatment to be initiated early. An additional bene®t may be that patients with less aggressive tumours may be spared unnecessary treatment.
Future research areas will focus on identifying enzymes responsible for the production of p27 and use them as targets for new drug treatment, which will aim to block p27 degradation and decrease the growth of speci®c tumours. 
